Showing 7541-7550 of 7740 results for "".
- Provectus Pharmaceuticals Publishes Patent Application, PV-10 Resultshttps://practicaldermatology.com/news/20121002-provectus_pharmaceuticals_publishes_patent_application/2459722/Provectus Pharmaceuticals, Inc. announced that a patent application has been published for US and international patents covering the combination of local and systemic immunomodulative therapies for cancer treatment. The patent, entitled "Combination
- Bovie Medical Promotes Double Warranty, Free Goodshttps://practicaldermatology.com/news/20121002-bovie_medical_promotes_double_warranty_free_goods/2459723/Bovie Medical Corporation started its Fall Festival of Fun promotion now through December 31, 2012. During the promotion, customers receive an increased value of a double warranty and free goods when purchasing the Aaron® 1250, Aaron® 2250, or Aaron® 3250. To find out more information contact a loca
- Aesthetics Course Offers Cosmetic Practitioners Practical Business Advicehttps://practicaldermatology.com/news/20121002-aesthetics_course_offers_cosmetic_practitioners_practical_business_advice/2459724/Registration is now open for “Mastering the Business of Aesthetics” (MBA), a one-day course that teaches vital lessons regarding the financial components of cosmetic practice. The course will take place in Beverly Hills, CA on October 27th and cover topics such as optimizing laser business, increasi
- Janssen Launches Online Resource for Healthcare Professionalshttps://practicaldermatology.com/news/20121002-janssen_launches_online_resource_for_healthcare_professionals/2459725/Janssen Scientific Affairs recently launched a new online scientific resource for U.S. healthcare professionals seeking instant access to current information about Janssen products marketed in the U.S. JanssenMD (www.janssenmd.com) is a web-based application is designed for use on desktops, tablets,
- Physician Pessimism, Dissatisfaction Highhttps://practicaldermatology.com/news/20120928-physician_pessimism_dissatisfaction_high/2459726/More than half of American physicians participating in a recent survey say they plan to significantly modify their practice patterns over the next one to three years, new research suggests. They report plans to cut back on patients seen, work part-time, switch to concierge medicine, retire, or take
- Star Scientific's Rock Creek Pharmaceuticals, Inc. Launches New Producthttps://practicaldermatology.com/news/20120926-star_scientifics_rock_creek_pharmaceuticals_inc_launches_new_product/2459728/Star Scientific, Inc., through its wholly owned subsidiary Rock Creek Pharmaceuticals, Inc., announced the new Anatabloc face cream, which is available on the cosmetic portion of the Anatabloc website and in select dermatology practices. The pro
- Lucid, Inc. Now Named Caliber IDhttps://practicaldermatology.com/news/20120926-lucid_inc_now_named_caliber_id/2459729/Lucid, Inc. announced that it is now operating under a new company name, Caliber Imaging & Diagnostics, Inc., or Caliber ID. Caliber ID has created an entirely new class of tools enabling physicians to image and diagnose skin disease in real tim
- New Practice Offers Personalized Procedureshttps://practicaldermatology.com/news/20120926-new_practice_offers_personalized_procedures/2459730/Dermatologist Candace Thornton Spann, MD, FAAD, and plastic surgeon Marvin Spann, MD, established a joint practice, Couture Dermatology & Plastic Surgery. The practice, which opens October 1, will offer custom-tailored treatments for all et
- Provectus Pharmaceuticals to Present Data on PV-10https://practicaldermatology.com/news/20120918-provectus_pharmaceuticals_to_present_data_on_pv-10/2459733/Provectus Pharmaceuticals, Inc. announced that final efficacy data from its Phase II trial of PV-10 in patients with Stage III-IV melanoma will be presented, including response rate and time-to-event (progression free survival and overall survival),
- p53R2 Regulates Proliferation and Chemosensitivity in Melanomahttps://practicaldermatology.com/news/20120918-p53r2_regulates_proliferation_and_chemosensitivity_in_melanoma/2459734/Expression of p53R2 significantly correlates with the depth of invasion and the tumor stage in melanoma, new research shows. (J Dermatol Sci; 68(1):19-24) Furthermore, use of siRNA targeting p53R2 successfully knocked down p53R2 and significantly inhibited the growth of KHm5 and 6 cells. The degree